BioPharm Insight™ Investigative Journalist to Host Expert Panel Discussing Biogenerics via Live Webinar on December 14, 2011

Share Article

Topics to be covered include FDA guidance, products, pathways and approvals

On December 14, 2011 at 10am ET, BioPharm Insight will host a live expert panel via online webinar discussing the biogenerics product landscape.

Featuring unbiased perspectives from subject matter experts Dr. Gillian Woollett of Avalere Health and Dr. Robert Bakin of Technology & Business Law Advisors, the interactive and complimentary webinar will cover critical topics including FDA guidance, products in development, pathways and approvals.

The webinar panel will be moderated by Jennifer Smith-Parker, BioPharm Insight Senior Journalist and D.C. Correspondent, and will feature an interactive Q&A session with attendees.

To participate in the event, register online at: https://www2.gotomeeting.com/register/765577586

Or, to request a recording, visit: http://www.zoomerang.com/Survey/WEB22DZQ8ZZHLN

The discussion is presented as part of BioPharm Insight’s ongoing series of educational webinars. BioPharm Insight is published by Infinata, a Mergermarket company.

About BioPharm Insight
BioPharm Insight is the definitive guide to the global life sciences community, combining forward-looking intelligence uncovered by an independent team of investigative journalists with the most comprehensive and powerful real-time database of market analytics and key contact information. BioPharm Insight is used by biopharma companies, CROs, service providers and financial markets firms to understand and interact with their industry. For a free trial of BioPharm Insight, visit http://www.biopharminsight.com.

About Infinata
Infinata provides personalized technology solutions to help clients turn information into insight. Featuring exclusive biopharmaceutical intelligence and business development tools such as BioPharm Insight™ and BioPharm Clinical™, Infinata helps biopharma companies, CROs, service providers and financial markets firms understand and become active participants in their global industry. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson PLC. To learn more, visit http://www.infinata.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Kris Sarajian
Infinata
781.702.6938
Email >
Visit website